Childhood Leukemia (ALL)

What is the CCCG-ALL Protocol?

The Chinese Children's Cancer Group ALL protocol is a risk-adapted, MRD-guided chemotherapy regimen for pediatric acute lymphoblastic leukemia. It has achieved cure rates comparable to top Western protocols while being tailored to the Asian pediatric population.

Why China?

• World-class cure rates: 5-year EFS >85% for standard risk ALL
• Cost (total treatment): $30,000-$60,000 vs. $300,000-$600,000 in the US
• MRD-guided therapy: Molecular monitoring at key time points
• Leading centers: Shanghai Children's Medical Center, Beijing Children's, Guangzhou Children's

Who is a candidate?

• Newly diagnosed pediatric ALL (age 1-18)
• Infant ALL (modified protocol)
• Relapsed ALL (combined with CAR-T in select cases)

Outcomes

5-year EFS: 85% standard risk, 75% intermediate risk, 60-65% high risk. 5-year OS: 90%+ standard risk. Treatment-related mortality: <3%. Long-term secondary malignancy: <2% at 10 years.